GCP
AVXL icon

GSA Capital Partners’s Anavex Life Sciences AVXL Stock Holding History

GSA Capital Partners’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,447
Closed -$133K – 1749
2026
Q1 		$133K Sell
43,447
-112,432
-72% -$487K 0.01% 1530
2025
Q4 		$555K Buy
155,879
+92,799
+147% +$569K 0.05% 738
2025
Q3 		$561K Buy
+63,080
New +$640K 0.05% 770
2025
Q2 		– Sell
-27,684
Closed -$238K – 1742
2025
Q1 		$238K Buy
+27,684
New +$261K 0.02% 1301
2024
Q4 		– Sell
-89,299
Closed -$507K – 1602
2024
Q3 		$507K Sell
89,299
-131,561
-60% -$759K 0.04% 896
2024
Q2 		$932K Buy
220,860
+199,965
+957% +$809K 0.07% 551
2024
Q1 		$106K Buy
+20,895
New +$118K 0.01% 1486
2023
Q3 		– Sell
-44,139
Closed -$359K – 1489
2023
Q2 		$359K Buy
+44,139
New +$378K 0.04% 942
2021
Q4 		– Sell
-30,301
Closed -$544K – 1405
2021
Q3 		$544K Buy
30,301
+13,298
+78% +$265K 0.06% 650
2021
Q2 		$389K Buy
+17,003
New +$252K 0.04% 787
2021
Q1 		– Sell
-49,678
Closed -$268K – 1092
2020
Q4 		$268K Buy
49,678
+20,194
+68% +$106K 0.04% 806
2020
Q3 		$134K Buy
+29,484
New +$127K 0.02% 1088

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GSA Capital Partners's AVXL Position: Q2 2026 in Review

GSA Capital Partners sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 43,447 shares — an estimated $133K sold.

GSA Capital Partners first reported a position in AVXL in Q3 2020 and held it in 12 quarters. The position peaked at $932K in Q2 2024. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • GSA Capital Partners reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 43,447 Anavex Life Sciences shares in Q2 2026, an estimated $133K.
  • GSA Capital Partners first reported a position in Anavex Life Sciences in Q3 2020 and held it in 12 quarters.
  • GSA Capital Partners's Anavex Life Sciences position peaked at $932K in Q2 2024.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.